Pam3CSK4 TFA
Modify Date: 2024-01-02 16:14:40
Pam3CSK4 TFA structure
|
Common Name | Pam3CSK4 TFA | ||
|---|---|---|---|---|
| CAS Number | 112208-01-2 | Molecular Weight | 1852.33 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C87H159F9N10O19S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Pam3CSK4 TFAPam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1]. |
| Name | Pam3CSK4 TFA |
|---|
| Description | Pam3CSK4 TFA is a toll-like receptor 1/2 (TLR1/2) agonist with an EC50 of 0.47 ng/mL for human TLR1/2[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Pam3CSK4 is a TLR1/2 heterodimer recognises triacylated lipopeptides[1]. Pam3CSK4 (1 μg/mL) enhances the antibacterial functions of granulocyte macrophage-colony stimulating factor (GM-CSF) induced neutrophils to Methicillin-resistant Staphylococcus aureus (MRSA)[2]. |
| In Vivo | Pam3CSK4 (5 mg/kg; i.p.; once a day for 9 days) alters brain, spleen and liver weights in neonatal mice[3]. Animal Model: Time-mated pregnant C57BL/6 wild-type mice; B6.129-Tlr2tm1Kir/J (TLR2 -deficient) mice[3] Dosage: 5 mg/kg Administration: Intraperitoneally (i.p.); once a day for 9 days Result: After repeated administration from postnatal day (PND3) to PND11, brain weight was decreased compared with endotoxin-free saline-treated animals at PND12. Decreased volume of cerebral gray matter, white matter in the forebrain and cerebellar molecular layer that was accompanied by an increase in spleen and liver weight at PND12. |
| References |
| Molecular Formula | C87H159F9N10O19S |
|---|---|
| Molecular Weight | 1852.33 |